市場調查報告書
商品編碼
1370384
蛋白質治療市場:2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測Protein Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年全球蛋白質治療市場規模達3,227億美元。展望未來,IMARC Group預計到2028年市場規模將達到4,870億美元,2023-2028年年複合成長率(CAGR)為7%。癌症、糖尿病、心血管疾病和自體免疫疾病等慢性疾病的盛行率不斷上升,蛋白質工程技術的快速進步,生物製藥行業的不斷擴大以及產品在不同治療領域的廣泛應用是推動市場發展的一些因素。
蛋白質療法是一類利用蛋白質或勝肽來預防、控制或治癒疾病的醫學治療方法。這些療法旨在針對體內的特定分子或途徑,提供高度針對性的治療方法。他們為多種疾病提供創新的解決方案,包括癌症、自體免疫疾病、遺傳性疾病等。它們可以來自天然來源,也可以透過重組 DNA 技術生產,從而可以開發高度特異性和有效的療法。這些治療性蛋白質可以採取多種形式,包括單株抗體、生長因子、酵素和細胞激素。它們與體內的特定受體或分子相互作用,調節細胞過程,抑製或刺激免疫反應,或直接針對致病因子。蛋白質療法的優點在於其高特異性、效力和低毒性。與傳統的小分子藥物相比,它們通常具有更高的療效和更少的副作用。他們大大推進了醫學領域的發展,提供了新穎的治療選擇並改善了各種疾病的患者治療結果。
全球市場的主要驅動力是對個人化醫療的日益關注。與此一致的是,不斷增加的研發活動和不斷擴大的醫療基礎設施正在為市場做出巨大貢獻。此外,製造流程的進步預計將推動市場的發展。除此之外,基因工程、蛋白質合成和生產技術的突破提高了蛋白質治療的效率和有效性,對市場產生了積極影響。此外,癌症、糖尿病、心血管疾病和自體免疫疾病等慢性疾病的日益普及正在催化市場。此外,蛋白質療法在腫瘤學中的廣泛應用正在刺激市場。此外,藥物輸送系統的快速創新改善了蛋白質治療藥物的輸送,提高了其療效和患者依從性。緩釋製劑、奈米顆粒和標靶藥物遞送系統等新型遞送方法可透過增加蛋白質藥物的治療潛力來推動市場成長。
不斷增加的生物製藥研發投資
由於蛋白質藥物具有高特異性、有效性和標靶性,生物製藥公司和研究機構越來越關注其開發。生物製藥領域研發投資的增加正在推動蛋白質療法的進步。這些投資支持與蛋白質工程、藥物發現和配方最佳化相關的研究活動,從而開發新型和改進的蛋白質療法。此外,分配給研發的大量資金使研究人員能夠探索新的治療靶點,最佳化蛋白質結構以增強活性,並進行廣泛的臨床前和臨床試驗。這些努力透過引入針對各種疾病的創新療法,有助於擴大市場。此外,不斷成長的研發投資有助於擴大蛋白質療法的生產流程,使其更容易獲得且更具成本效益。這使得蛋白質藥物的商業化和市場滲透率得到提高。
生物相似藥的擴展
生物相似藥市場的擴張對市場做出了重大貢獻。生物相似藥是與已核准的參考蛋白治療藥物高度相似的生物藥物。隨著幾種重磅生物製劑的專利到期,生物相似藥市場正在迅速擴大。生物相似藥的出現為昂貴的蛋白質療法提供了具有成本效益的替代品,使患者和醫療保健系統更容易獲得它們。負擔能力的提高使患者能夠獲得必要的治療,從而推動市場成長。此外,生物相似藥的引入促進了市場競爭。競爭導致價格下降,鼓勵市場擴張,並為生物相似藥製造商和參考蛋白治療公司創造創新和改進產品的機會。此外,生物相似藥的監管框架和指南已經更加完善和簡化,為其開發和批准提供了明確的途徑。這給醫療保健界注入了信心,並導致生物相似藥的採用增加。隨著生物相似藥市場的擴大,它刺激了蛋白質療法的進一步研究和開發工作。製造商努力開發更先進和差異化的生物相似藥,為市場創造了積極的前景。
人口老化加劇
人口老化的加劇對市場有正面影響。隨著全球人口老化,阿茲海默症、帕金森氏症、黃斑部病變和骨質疏鬆症等與年齡相關的疾病和病症的盛行率更高。蛋白質療法正在開發和利用,以解決老齡化人口面臨的這些特定健康挑戰。此外,蛋白質療法為與年齡相關的疾病提供了有針對性的治療選擇,與傳統療法相比,可以提高療效並減少副作用。它們可以針對特定的分子途徑並解決這些疾病的潛在機制,從而改善患者的治療結果和生活品質。此外,老齡化人口不斷成長的產品需求正在推動市場成長。製藥公司和研究機構正在投資開發新型蛋白質療法,以滿足這一人群的特定需求。此外,日益成長的老齡化人口為蛋白質治療創造了更大的市場,促使製造商擴大產品組合併增加產量。這反過來又導致蛋白質療法的更廣泛應用並進一步推動市場成長。
IMARC Group 提供了全球蛋白質治療市場報告各細分市場主要趨勢的分析,以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據產品、治療領域和功能對市場進行了分類。
單株抗體 (mAb)
人類胰島素
促紅血球生成素
凝血因子
融合蛋白
其他
單株抗體 (mAb) 主導市場
該報告根據產品提供了詳細的市場細分和分析。這包括單株抗體 (mAb)、人類胰島素、促紅血球生成素、凝血因子、融合蛋白等。根據該報告,單株抗體(mAb)代表了最大的部分。
單株抗體 (mAb) 廣泛用於治療癌症、自體免疫疾病和發炎性疾病。這些疾病的日益普遍,加上抗體工程和生產技術的進步,推動了對單株抗體的需求並促進了市場的成長。
另一方面,人類胰島素是治療糖尿病的重要蛋白質療法。隨著全球糖尿病發生率的上升,對胰島素和胰島素類似物的需求不斷增加,導致該領域的市場成長。此外,促紅血球生成素(EPO)是另一種刺激紅血球生成的重要治療蛋白。它用於治療貧血,特別是患有慢性腎臟病和接受化療的癌症患者。需要 EPO 治療的患者群體不斷擴大正在推動這一領域的成長。
除此之外,凝血因子是血液凝固所必需的蛋白質。它們用於治療血友病等出血性疾病。對血友病的認知、診斷和治療的不斷成長推動了對凝血因子的需求並為市場做出了貢獻。此外,結合兩個或多個功能性蛋白結構域的融合蛋白在創新療法的開發中受到了極大的關注。他們為包括癌症和自體免疫疾病在內的各種疾病提供獨特的治療方法,從而推動了該領域的市場。
代謝紊亂
免疫系統疾病
血液系統疾病
癌症
荷爾蒙失調
遺傳性疾病
其他
代謝紊亂佔據最大的市場佔有率
報告還提供了基於治療領域的詳細市場細分和分析。這包括代謝失調、免疫失調、血液失調、癌症、荷爾蒙失調、遺傳失調等。報告稱,代謝紊亂佔據了最大的市場佔有率。
代謝紊亂包括糖尿病、肥胖症和高膽固醇血症等病症。蛋白質療法,例如用於糖尿病管理的胰島素,對於治療和控制這些疾病至關重要。代謝紊亂的盛行率不斷上升,加上對有針對性的有效治療的需求不斷增加,正在推動該領域市場的成長。
相反,免疫性疾病,包括自體免疫疾病和發炎性疾病,代表了蛋白質療法的另一個重要治療領域。單株抗體和其他以蛋白質為基礎的藥物可調節免疫系統並針對特定的疾病途徑。免疫系統疾病的發生率不斷上升,以及針對這些疾病的批准的蛋白質療法範圍不斷擴大,正在推動市場的發展。
此外,癌症仍然是市場的主要驅動力之一。基於蛋白質的療法,包括單株抗體、抗體藥物偶聯物和免疫檢查點抑制劑,已經徹底改變了癌症治療。全球癌症發生率不斷上升,加上標靶療法和免疫療法的發展,正在推動腫瘤學市場的成長。
酶促和調節活性
特別目標活動
疫苗
蛋白質診斷
報告還根據功能對市場進行了詳細的細分和分析。這包括酶促和調節活性、特殊靶向活性、疫苗和蛋白質診斷。
具有酶活性和調節活性的蛋白質療法對於調節生物過程和代謝途徑至關重要。這些蛋白質可作為酵素、受體或訊號分子,為各種疾病提供治療益處。具有特定酶或調節功能的新型蛋白質療法的開發推動了該領域的市場成長。
此外,特殊標靶活性是指針對某些細胞、組織或分子標靶的蛋白質治療。單株抗體和抗體藥物偶聯物是具有特殊標靶活性的蛋白質療法的例子。它們可以精確識別並結合特定分子或細胞,提供高度針對性的治療。癌症和自體免疫疾病等疾病對標靶治療的需求不斷成長,推動了該領域蛋白質療法的成長。
此外,疫苗是市場的另一個重要部分。基於蛋白質的疫苗利用特定的蛋白質或勝肽來刺激免疫反應並賦予針對傳染病的免疫力。全球對疫苗接種計劃的關注、新傳染病的出現以及對改進疫苗技術的需求推動了該領域的市場成長。
此外,蛋白質診斷涉及使用蛋白質或基於蛋白質的測定來進行診斷。這些診斷可以檢測與疾病相關的特定蛋白質或生物標記物,有助於早期檢測、疾病監測和個人化治療。對準確可靠的診斷工具的需求不斷成長,推動了蛋白質診斷的成長,並對整個市場做出了貢獻。
北美洲
美國
加拿大
亞太地區
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美表現出明顯的主導地位,佔據最大的蛋白質治療市場佔有率
該報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。
北美,尤其是美國,佔有重要的市場佔有率。該地區受益於先進的醫療基礎設施、強大的生物製藥公司以及強勁的研發活動。主要參與者的存在和對蛋白質治療研究的廣泛投資有助於北美市場的成長。此外,慢性病盛行率高、人口老化程度高以及有利的報銷政策進一步推動了該地區的市場。
另一方面,亞太地區正成為一個快速成長的市場。該地區人口基數大,醫療支出不斷增加,慢性病盛行率不斷上升。中國、日本和印度等國家的生物製藥產業和研發投資都在大幅成長。此外,對個人化醫療的認知不斷增強,以及對具有成本效益的治療方案的需求不斷成長,正在推動蛋白質療法在亞太地區的採用。
頂尖公司正在大力投資科學研究,以確定新的治療標靶並開發具有更高功效和安全性的蛋白質藥物。他們利用蛋白質工程、分子生物學和生物技術專業知識來設計和最佳化治療性蛋白質。此外,這些公司與學術機構、研究組織和其他製藥公司建立策略合作,以獲取新技術、擴大管道並加速開發。合作促進知識、資源和專業知識的交流,促進創新並推動市場發展。此外,成功的商業化策略在推動市場成長方面發揮著至關重要的作用。這些公司採用強大的行銷和銷售努力,向世界各地的醫療保健提供者和患者推廣和分銷其產品。他們進行廣泛的臨床試驗,產生令人信服的臨床資料,並獲得監管部門的批准以確保市場准入。此外,頂尖公司不斷投資於製造能力和品質控制系統,以滿足不斷成長的需求並確保其產品的持續供應。這種對卓越製造的承諾幫助他們滿足患者、醫療保健提供者和付款人的需求,進一步推動市場成長。
安進公司
雅培實驗室
艾伯維公司
百特國際公司
百健公司
Csl Behring LLC(CSL 有限公司)
禮來公司
F.霍夫曼-拉羅氏股份公司(羅氏控股股份公司)
強生公司
默克公司
諾和諾德公司 (Novo Holdings A/S)
輝瑞公司
2020 年,安進公司 (Amgen Inc.) 與 Adaptive Biotechnologies 合作,開發並商業化針對 SARS-CoV-2(引起 COVID-19 的病毒)的完全人類中和抗體。
2021 年,雅培實驗室 (Abbott Laboratories) 的 Tendyne 經導管二尖瓣置換 (TMVR) 系統獲得 FDA 批准,這是一種針對嚴重二尖瓣逆流患者的微創療法。
2020 年,艾伯維公司 (AbbVie Inc.) 收購了艾爾建 (Allergan),這是一家以其美容和治療產品組合而聞名的製藥公司,其中包括 Botox。
The global protein therapeutics market size reached US$ 322.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 487.0 Billion by 2028, exhibiting a growth rate (CAGR) of 7% during 2023-2028. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders, the rapid technological advancements in protein engineering, the expanding biopharmaceutical industry, and the widespread product applications in diverse therapeutic areas are some factors propelling the market.
Protein therapeutics is a class of medical treatments utilizing proteins or peptides to prevent, manage, or cure diseases. These therapeutics are designed to target specific molecules or pathways within the body, providing a highly targeted approach to treatment. They offer innovative solutions for a wide range of conditions, including cancer, autoimmune disorders, genetic diseases, and more. They can be derived from natural sources or produced through recombinant DNA technology, allowing for the development of highly specific and potent therapies. These therapeutic proteins can take various forms, including monoclonal antibodies, growth factors, enzymes, and cytokines. They interact with specific receptors or molecules in the body, modulating cellular processes, inhibiting or stimulating immune responses, or directly targeting disease-causing agents. The advantages of protein therapeutics lie in their high specificity, potency, and low toxicity. They often offer improved efficacy and fewer side effects than traditional small-molecule drugs. They have significantly advanced the field of medicine, providing novel treatment options and improving patient outcomes across various diseases.
The global market is majorly driven by the increasing focus on personalized medicine. In line with this, the rising research and development activities and the expanding healthcare infrastructure are significantly contributing to the market. Furthermore, the advancements in manufacturing processes are expected to fuel the market. Apart from this, the breakthroughs in genetic engineering, protein synthesis, and production technologies have enhanced the efficiency and effectiveness of protein therapeutics, positively influencing the market. Moreover, the growing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is catalyzing the market. Besides, the widespread applications of protein therapeutics in oncology are stimulating the market. Additionally, the rapid innovations in drug delivery systems have improved the delivery of protein therapeutics, enhancing their efficacy and patient compliance. Novel delivery methods such as sustained-release formulations, nanoparticles, and targeted drug delivery systems are driving the market growth by increasing the therapeutic potential of protein drugs.
Growing biopharmaceutical research and development investments
Biopharmaceutical companies and research institutions are increasingly focusing on the development of protein-based drugs due to their high specificity, efficacy, and targetability. The rise in R&D investments in the biopharmaceutical sector is fueling advancements in protein therapeutics. These investments support research activities related to protein engineering, drug discovery, and formulation optimization, leading to the development of novel and improved protein therapeutics. Furthermore, the substantial funds allocated to R&D enable researchers to explore new therapeutic targets, optimize protein structures for enhanced activity, and conduct extensive preclinical and clinical trials. These efforts contribute to the expansion of the market by introducing innovative treatments for various diseases. Moreover, the growing R&D investments facilitate the scaling-up of production processes for protein therapeutics, making them more accessible and cost-effective. This enables increased commercialization and market penetration of protein-based drugs.
Expansion of biosimilars
The expansion of the biosimilars market is significantly contributing to the market. Biosimilars are biologic drugs that are highly similar to approved reference protein therapeutics. As patents for several blockbuster biologics expire, the market for biosimilars is expanding rapidly. The availability of biosimilars provides cost-effective alternatives to expensive protein therapeutics, making them more accessible to patients and healthcare systems. This increased affordability enhances patient access to necessary treatments, driving market growth. Furthermore, the introduction of biosimilars fosters competition in the market. Competition leads to price reductions, encouraging market expansion and creating opportunities for biosimilar manufacturers and reference protein therapeutics companies to innovate and improve their products. Moreover, the regulatory frameworks and guidelines for biosimilars have become more established and streamlined, providing a clear pathway for their development and approval. This has instilled confidence in the healthcare community and resulted in increased biosimilar adoption. As the biosimilars market expands, it stimulates further research and development efforts in protein therapeutics. Manufacturers strive to develop more advanced and differentiated biosimilars, creating a positive outlook for the market.
Rising aging population
The rising aging population is positively influencing the market. As the global population ages, there is a higher prevalence of age-related diseases and conditions such as Alzheimer's disease, Parkinson's disease, macular degeneration, and osteoporosis. Protein therapeutics are being developed and utilized to address these specific health challenges the aging population faces. Furthermore, protein therapeutics offer targeted treatment options for age-related diseases, providing improved efficacy and reduced side effects as compared to traditional therapies. They can target specific molecular pathways and address the underlying mechanisms of these diseases, thereby improving patient outcomes and quality of life. Moreover, the increasing product demand among the aging population is driving market growth. Pharmaceutical companies and research institutions are investing in the development of novel protein therapeutics to meet the specific needs of this demographic. Additionally, the growing aging population creates a larger market for protein therapeutics, prompting manufacturers to expand their product portfolios and increase production. This, in turn, leads to a wider availability of protein therapeutics and further drives market growth.
IMARC Group provides an analysis of the key trends in each segment of the global protein therapeutics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, therapy area, and function.
Monoclonal Antibodies (mAbs)
Human Insulin
Erythropoietin
Clotting Factors
Fusion Protein
Others
Monoclonal Antibodies (mAbs) dominates the market
The report has provided a detailed breakup and analysis of the market based on product. This includes monoclonal antibodies (mAbs), human insulin, erythropoietin, clotting factors, fusion protein, and others. According to the report, monoclonal antibodies (mAbs) represented the largest segment.
Monoclonal antibodies (mAbs) are extensively used to treat cancer, autoimmune disorders, and inflammatory diseases. The increasing prevalence of these conditions, coupled with advancements in antibody engineering and production technologies, drives the demand for mAbs and contributes to the market growth.
On the other hand, human insulin is a vital protein therapeutic for managing diabetes. With the rising incidence of diabetes worldwide, the demand for insulin and insulin analogs is increasing, leading to market growth in this segment. Moreover, erythropoietin (EPO) is another important therapeutic protein stimulating red blood cell production. It is used to treat anemia, particularly in patients with chronic kidney disease and cancer undergoing chemotherapy. The expanding patient pool requiring EPO therapy is driving the growth of this segment.
Besides this, the clotting factors are proteins essential for blood clotting. They are used to manage bleeding disorders such as hemophilia. The growing awareness, diagnosis, and treatment of hemophilia fuel the demand for clotting factors and contribute to the market. In addition, fusion proteins, which combine two or more functional protein domains, have gained significant attention in the development of innovative therapeutics. They offer unique treatment approaches for various diseases, including cancer and autoimmune disorders, thus driving the market in this segment.
Metabolic Disorders
Immunological Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others
Metabolic Disorders holds the largest share of the market
A detailed breakup and analysis of the market based on the therapy area have also been provided in the report. This includes metabolic disorders, immunological disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. According to the report, metabolic disorders accounted for the largest market share.
Metabolic disorders encompass conditions such as diabetes, obesity, and hypercholesterolemia. Protein therapeutics, such as insulin for diabetes management, are crucial in treating and controlling these disorders. The rising prevalence of metabolic disorders, coupled with the increasing demand for targeted and effective treatments, is driving the growth of the market in this segment.
On the contrary, immunological disorders, including autoimmune diseases and inflammatory conditions, represent another significant therapy area for protein therapeutics. Monoclonal antibodies and other protein-based drugs modulate the immune system and target specific disease pathways. The growing incidence of immunological disorders and the expanding range of approved protein therapeutics for these conditions are driving the market.
In addition, cancer remains one of the primary drivers of the market. Protein-based therapies, including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, have revolutionized cancer treatment. The increasing incidence of cancer globally, coupled with the development of targeted therapies and immunotherapies, is propelling the growth of the market in oncology.
Enzymatic and Regulatory Activity
Special Targeting Activity
Vaccines
Protein Diagnostics
A detailed breakup and analysis of the market based on the function have also been provided in the report. This includes enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics.
Protein therapeutics with enzymatic and regulatory activity are vital in modulating biological processes and metabolic pathways. These proteins act as enzymes, receptors, or signaling molecules, offering therapeutic benefits in various diseases. The development of novel protein therapeutics with specific enzymatic or regulatory functions drives market growth in this segment.
Furthermore, special targeting activity refers to protein therapeutics targeting certain cells, tissues, or molecular targets. Monoclonal antibodies and antibody-drug conjugates are examples of protein therapeutics with special targeting activity. They can precisely recognize and bind to specific molecules or cells, providing highly targeted therapies. The increasing demand for targeted treatments in conditions such as cancer and autoimmune diseases fuels the growth of protein therapeutics in this segment.
Moreover, vaccines are another significant segment in the market. Protein-based vaccines utilize specific proteins or peptides to stimulate an immune response and confer immunity against infectious diseases. The global focus on vaccination programs, the emergence of new infectious diseases, and the need for improved vaccine technologies drive market growth in this segment.
Besides, protein diagnostics involves using proteins or protein-based assays for diagnostic purposes. These diagnostics can detect specific proteins or biomarkers associated with diseases, aiding in early detection, disease monitoring, and personalized treatment. The growing demand for accurate and reliable diagnostic tools fuels the growth of protein diagnostics and contributes to the overall market.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest protein therapeutics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
North America, particularly the United States, holds a significant market share. The region benefits from advanced healthcare infrastructure, a strong presence of biopharmaceutical companies, and robust research and development activities. The presence of key players and extensive investments in protein therapeutics research contribute to market growth in North America. Additionally, the high prevalence of chronic diseases, a large aging population, and favorable reimbursement policies further drive the market in the region.
On the other hand, Asia Pacific is emerging as a rapidly growing market. The region has a large population base, increasing healthcare expenditure, and a rising prevalence of chronic diseases. Countries such as China, Japan, and India are witnessing substantial growth in the biopharmaceutical industry and investing in research and development. Moreover, the increasing awareness of personalized medicine and growing demand for cost-effective treatment options are driving the adoption of protein therapeutics in Asia Pacific.
Top companies are investing heavily in scientific research to identify new therapeutic targets and develop protein-based drugs with enhanced efficacy and safety profiles. They leverage their protein engineering, molecular biology, and biotechnology expertise to design and optimize therapeutic proteins. Furthermore, these companies establish strategic collaborations with academic institutions, research organizations, and other pharmaceutical companies to access new technologies, expand their pipelines, and accelerate development. Collaborations enable the exchange of knowledge, resources, and expertise, fostering innovation and driving the market. Moreover, successful commercialization strategies play a vital role in driving market growth. These companies employ robust marketing and sales efforts to promote and distribute their products to healthcare providers and patients worldwide. They conduct extensive clinical trials, generate compelling clinical data, and obtain regulatory approvals to ensure market access. Additionally, the top companies continuously invest in manufacturing capabilities and quality control systems to meet the growing demand and ensure a consistent supply of their products. This commitment to manufacturing excellence helps them meet the needs of patients, healthcare providers, and payers, further driving the market growth.
Amgen Inc.
Abbott Laboratories
Abbvie Inc.
Baxter International Inc.
Biogen Inc.
Csl Behring L.L.C. (CSL Limited)
Eli Lilly and Company
F. Hoffmann-La Roche AG (Roche Holding AG)
Johnson & Johnson
Merck & Co. Inc.
Novo Nordisk A/S (Novo Holdings A/S)
Pfizer Inc.
In 2020, Amgen Inc. entered into a collaboration with Adaptive Biotechnologies to develop and commercialize fully human-neutralizing antibodies targeting SARS-CoV-2, the virus that causes COVID-19.
In 2021, Abbott Laboratories received FDA clearance for their Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, a minimally invasive therapy for patients with severe mitral regurgitation.
In 2020, AbbVie Inc. acquired Allergan, a pharmaceutical company known for its portfolio of aesthetic and therapeutic products, including Botox.